Deal News
Ingersoll Rand to expand life science presence with $2.3bn ILC buyout
Ingersoll Rand has signed an agreement for the acquisition of ILC Dover from investment company New Mountain Capital for $2.325bn…
Nuvation Bio to acquire AnHeart to form global oncology company
Nuvation Bio has made a definitive agreement to acquire AnHeart Therapeutics through an all-stock transaction, in a strategic move to…
AbbVie signs agreement to acquire Landos Biopharma for $212.5m
AbbVie has entered a definitive agreement to acquire clinical-stage biopharmaceutical company Landos Biopharma for $212.5m. The strategic acquisition boosts AbbVie's…
Novo shells out $1.1bn to buy Cardior to expand cardiovascular pipeline
Novo Nordisk has agreed to acquire Germany-based Cardior Pharmaceuticals for up to €1bn ($1.1bn) to expand its cardiovascular pipeline. The…
Gilead acquires CymaBay Therapeutics for $4.3bn
Gilead Sciences has concluded the acquisition of CymaBay Therapeutics for $4.3bn. The strategic move was finalised following the closure of…
Bristol Myers Squibb acquires Karuna Therapeutics for $14bn
Bristol Myers Squibb (BMS) has concluded the acquisition of biopharmaceutical company Karuna Therapeutics for $14bn in cash. The transaction was finalised…
AstraZeneca snaps up Amolyt for $1.05bn to boost rare disease pipeline
AstraZeneca has signed a definitive agreement to acquire Amolyt Pharma, which specialises in therapies for rare endocrine diseases, in a…
Novartis exercises option to acquire IFM Due for $835m
Novartis has exercised an option for the acquisition of all outstanding capital stock of IFM Therapeutics subsidiary IFM Due for…
Merck completes acquisition of Harpoon Therapeutics
Merck & Co. (MSD) has concluded the acquisition of Harpoon Therapeutics to broaden its oncology pipeline. In January 2024, MSD…
Johnson & Johnson acquires Ambrx Biopharma for $2bn
Johnson & Johnson (J&J) has concluded the acquisition of clinical-stage biopharmaceutical company Ambrx Biopharma in a $2bn transaction. The companies…